Our mission: to improve the lives of patients suffering from neurological diseases or injury to the central nervous system. We develop novel drug treatments and diagnostic approaches to reduce symptoms, disability and pain by targeting neuro-toxins which increase inflammation and damage nerve cells.
Neuro Vigor’s intellectual property is enabling development of more accurate diagnostics for the root causes of CNS disability and pain. Neuro Vigor Rx therapies are then precisely targeted to mitigate and potentially eliminate neuro-toxins associated with tissue inflammation and damaged nerve cells which result from these diseases. There are acute unmet needs for effective therapies with reduced side effects to address disorders such as multiple sclerosis, Parkinson’s disease, and neuropathic pain which are Neuro Vigor’s pipeline development priorities.
Neuro Vigor was founded in 2013 to monetize 15 years of path-breaking research of its co-founder, Dr. Riyi Shi, an internationally recognized Neurosciences MD and researcher who discovered the links between a specific neuro-toxin, Acrolein, and multiple neurological conditions. In animal studies, he also identified specific drugs which reduce Acrolein levels resulting in improvement in CNS symptoms. Neuro Vigor has protocols in place for advanced pre-clinical work designed to prepare the company for an FDA pre-IDE meeting focused on its first Acrolein Scavenger Rx product for multiple sclerosis.
In summary, Neuro Vigor’s focus and priority is an FDA cleared drug and companion diagnostic for MS. This product will favorably impact the remit & relapse cycles associated with MS and delay disease progression.
Recent News & Media
- Purdue News, June 13, 2013 Testing method promising for spinal cord injuries, multiple sclerosis
- PMC February, 2011 NEUROLOGIC HEALTH: Acrolein and Neuro Disorders
- Purdue University News Service, November 23, 2010 Findings suggest new cause, possible treatment for multiple sclerosis